Pulmonx Corporation, based in Redwood City, Calif., is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders.
The company is currently engaged in the design, development and manufacture of products that will improve the effectiveness and benefits of endoscopic lung volume reduction (ELVR) for patients with severe emphysema. The companyâ€™s ZephyrÂ® Endobronchial Valve (EBV) therapy* involves placing small one-way valves in the lung to prevent air from entering the most diseased regions while allowing fluids and trapped air to escape. The goal is to reduce the volume of the diseased portions of the lung, allowing increased ventilation to healthier areas of the lung.
The company has CE mark for the Zephyr Endobronchial Valves and has submitted a CE mark application for the Chartis System. The company has 510(k) marketing clearance for the Chartis System in the United States.
Past Team (2)Update
Funding Rounds (4) - $73.5MUpdate
Montreux Equity Partners is a private investment firm dedicated to building the leading...
Identifies and invests in new medical technologies and the entrepreneurs developing them to...
DeNovo Ventures was formed in 2000 by seasoned investors and experienced medical device...
Early stage healthcare
Venture Capital Firm
POSCO BioVentures' primary investment focus is on companies with novel, proprietary...
Live-sciences focused fund-of-funds
700 Chesapeake Drive
Redwood City, CA 94063